Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)
NCT ID: NCT00615563
Last Updated: 2013-11-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
246 participants
OBSERVATIONAL
2007-03-31
2008-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
genotype test
NO BI Drug administered
combined phenotype/genotype test
NO BI Drug administered
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NO BI Drug administered
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. HIV-1 infected male or female ?18 years of age.
3. Have confirmed (2 consecutive) HIV RNA ?1000 copies/mL (one of the results must be within 3 months of enrollment into the study).
4. Current HAART regimen contains a protease inhibitor for ?3 months.
5. Physicians considering a change in the patient?s HAART regimen. f.) History of treatment with 2 or more protease inhibitors (including the current PI). Low dose ritonavir (i.e.\< 400 mg. bid) is not counted as one of the PIs.
Exclusion Criteria
1. ARV medication naive.
2. Active opportunistic infection. c.) Known or suspected non-adherence to current HAART regimen as assessed by the investigator.
18 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Boehringer Ingelheim Study Coordinator
Role: STUDY_CHAIR
B.I. Pharmaceuticals,Inc./Ridgefield
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Boehringer Ingelheim Investigational Site
Bakersfield, California, United States
Boehringer Ingelheim Investigational Site
Beverly Hills, California, United States
Boehringer Ingelheim Investigational Site
Fountain Valley, California, United States
Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
Boehringer Ingelheim Investigational Site
Newport Beach, California, United States
Boehringer Ingelheim Investigational Site
Oakland, California, United States
Boehringer Ingelheim Investigational Site
Stanford, California, United States
Boehringer Ingelheim Investigational Site
Daytona Beach, Florida, United States
Boehringer Ingelheim Investigational Site
Fort Lauderdale, Florida, United States
Boehringer Ingelheim Investigational Site
Fort Lauderdale, Florida, United States
Boehringer Ingelheim Investigational Site
Miami, Florida, United States
Boehringer Ingelheim Investigational Site
Miami, Florida, United States
Boehringer Ingelheim Investigational Site
North Palm Beach, Florida, United States
Boehringer Ingelheim Investigational Site
Pensacola, Florida, United States
Boehringer Ingelheim Investigational Site
Chicago, Illinois, United States
Boehringer Ingelheim Investigational Site
New Orleans, Louisiana, United States
Boehringer Ingelheim Investigational Site
Baltimore, Maryland, United States
Boehringer Ingelheim Investigational Site
Springfield, Massachusetts, United States
Boehringer Ingelheim Investigational Site
Berkley, Michigan, United States
Boehringer Ingelheim Investigational Site
St Louis, Missouri, United States
Boehringer Ingelheim Investigational Site
Camden, New Jersey, United States
Boehringer Ingelheim Investigational Site
Newark, New Jersey, United States
Boehringer Ingelheim Investigational Site
Newark, New Jersey, United States
Boehringer Ingelheim Investigational Site
Voorhees Township, New Jersey, United States
Boehringer Ingelheim Investigational Site
Rochester, New York, United States
Boehringer Ingelheim Investigational Site
Charlotte, North Carolina, United States
Boehringer Ingelheim Investigational Site
Huntersville, North Carolina, United States
Boehringer Ingelheim Investigational Site
Akron, Ohio, United States
Boehringer Ingelheim Investigational Site
Portland, Oregon, United States
Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
Boehringer Ingelheim Investigational Site
Fort Worth, Texas, United States
Boehringer Ingelheim Investigational Site
Houston, Texas, United States
Boehringer Ingelheim Investigational Site
Hampton, Virginia, United States
Boehringer Ingelheim Investigational Site
Ponce, , Puerto Rico
Boehringer Ingelheim Investigational Site
Ponce, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1182.116
Identifier Type: -
Identifier Source: org_study_id